EntryPoint Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

EntryPoint Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$167K	Buy	17,561 +4,870	+38%	+$37.8K	0.05%	670
2025 Q4	$99K	Sell	12,691 -29,623	-70%	-$214K	0.04%	610
2025 Q3	$321K	Buy	42,314 +3,289	+8%	+$27.4K	0.12%	338
2025 Q2	$350K	Sell	39,025 -1,503	-4%	-$14K	0.18%	216
2025 Q1	$304K	Buy	+40,528	New	+$327K	0.14%	319
2024 Q4	–	Sell	-53,763	Closed	-$409K	–	729
2024 Q3	$409K	Buy	+53,763	New	+$409K	0.23%	116
2024 Q2	–	Sell	-42,679	Closed	-$217K	–	918
2024 Q1	$217K	Buy	42,679 +37,275	+690%	+$210K	0.19%	92
2023 Q4	$32.4K	Buy	+5,404	New	+$31.3K	0.03%	895

Other funds holding BCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return